$41.30
2.03% today
NYSE, Feb 05, 04:23 pm CET
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Apogee Therapeutics Stock price

$40.48
-7.81 16.17% 1M
-0.44 1.08% 6M
-4.82 10.64% YTD
+4.48 12.44% 1Y
+19.25 90.67% 3Y
+19.25 90.67% 5Y
+19.25 90.67% 10Y
NYSE, Closing price Tue, Feb 04 2025
+0.11 0.27%
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Key metrics

Market capitalization $2.37b
Enterprise Value $1.85b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.23
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-178.14m
Free Cash Flow (TTM) Free Cash Flow $-134.53m
Cash position $526.05m
EPS (TTM) EPS $-2.73
P/E forward negative
Short interest 21.98%
Show more

Is Apogee Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Apogee Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Apogee Therapeutics forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Apogee Therapeutics forecast:

Buy
100%

Financial data from Apogee Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.11 0.11
-
-
-0.11 -0.11
-
-
- Selling and Administrative Expenses 41 41
-
-
- Research and Development Expense 137 137
-
-
-178 -178
-
-
- Depreciation and Amortization 0.11 0.11
-
-
EBIT (Operating Income) EBIT -178 -178
-
-
Net Profit -147 -147
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Apogee Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apogee Therapeutics Stock News

Neutral
GlobeNewsWire
2 days ago
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the ...
Neutral
GlobeNewsWire
7 days ago
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T.
Neutral
GlobeNewsWire
2 months ago
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
More Apogee Therapeutics News

Company Profile

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Henderson
Founded 2022
Website www.apogeetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today